SCHEMBL3015084

SCHEMBL3015084

COc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4cccc(Cl)c4)CC3)n2)cc1OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.48
POLB P06746 1/20 0.48
HTT P42858 1/20 0.48
HTR7 P34969 1/20 0.46
HSD17B10 Q99714 3/20 0.44
USP2 O75604 2/20 0.44
LMNA P02545 2/20 0.44
GLA P06280 1/20 0.44
MAPK1 P28482 1/20 0.44
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
MAPT P10636 3/20 0.43
RECQL P46063 1/20 0.43
HSD11B1 P28845 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
RAB9A P51151 1/20 0.43
HDAC3 O15379 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3013018 0.92 TSHR (0.43) TSHRPOLBHTTHTR7HSD17B10
SCHEMBL3019397 0.91 USP2 (0.45) TSHRPOLBHTTHTR7HSD17B10
SCHEMBL3007865 0.90 GAA (0.49) TSHRPOLBHTTHSD17B10USP2
SCHEMBL3013884 0.90 TSHR (0.53) TSHRPOLBHTTHSD17B10USP2
SCHEMBL3001739 0.90 MEN1 (0.53) TSHRPOLBHTTHSD17B10USP2
SCHEMBL3017968 0.90 TSHR (0.48) TSHRPOLBHTTHSD17B10USP2
SCHEMBL3016611 0.89 TSHR (0.47) TSHRPOLBHTTHSD17B10USP2
SCHEMBL3016067 0.89 ALDH1A1 (0.51) TSHRPOLBHTTHSD17B10USP2
SCHEMBL3006268 0.89 PKM (0.47) TSHRPOLBHTTHSD17B10USP2
SCHEMBL3015962 0.89 MAPT (0.52) TSHRPOLBHTTHSD17B10USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA TSHR 3320/4885POLB 4649/4885HTT 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.